DiaMedica Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.59 USD | +0.78% | +3.19% | -8.80% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.80% | 98.31M | |
-2.63% | 102B | |
+1.62% | 96.29B | |
+1.63% | 22.18B | |
-16.67% | 21.2B | |
-8.54% | 18.31B | |
-38.74% | 17.38B | |
-13.21% | 16.36B | |
+5.41% | 13.97B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- DMAC Stock
- News DiaMedica Therapeutics Inc.
- DiaMedica Therapeutics Inc. Announces That the FDA Has Removed the Clinical Hold on Dm199 Phase 2/3 Trial Forschemic Stroke